A comparative study of the effects of imeglimin add‐on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low‐dose metformin ( MEGMI‐CGM study)

Documenti analoghi

• Similarities and differences in the intestinal actions of metformin and imeglimin
  di: Kenji Sugawara, et al.
  Pubblicazione: (2025)
• Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP ‐ ELM study
  di: Maiko Miyamoto, et al.
  Pubblicazione: (2026)
• Effects of glucokinase haploinsufficiency on the pancreatic β‐cell mass and function of long‐term high‐fat, high‐sucrose diet‐fed mice
  di: Ikumi Shigesawa, et al.
  Pubblicazione: (2024)
• Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post‐hoc analysis of imeglimin clinical trial data
  di: Jumpei Ito, et al.
  Pubblicazione: (2024)
• Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
  di: Leili Gao, et al.
  Pubblicazione: (2025)